AECOPD | Controls | |
Subjects | 30 | 30 |
Sex | ||
Female | 20 (67) | 9 (30) |
Male | 10 (33) | 21(70) |
Age years | ||
Mean | 75±7.7 | 71±13 |
Median | 76 | 71 |
Comorbidities (patient-reported) | ||
Diabetes | 7 (23) | 9 (30) |
Atrial fibrillation | 5 (17) | 0 |
Congestive heart failure | 3 (10) | 0 |
Hypertension | 3 (10) | 2 (7) |
Angina | 3 (10) | 3 (10) |
Asthma | 0 | 4 (13) |
Reflux | 5 (17) | 11 (37) |
GOLD stage | ||
1 | 0 (0) | |
2 | 5 (17) | |
3 | 15 (50) | |
4 | 10 (33) | |
Spirometry | ||
FEV1 % pred | 36±15 | |
FEV1/FVC | 43.5±13.1 | |
Respiratory rate breaths·min−1 | 21±6 | 20±6 |
Smoking | ||
Current | 6 (20) | 2 (7) |
Former | 23 (77) | 14 (47) |
Never | 1 (3) | 14 (47) |
BMI kg·m−2 | 24±6.4 | 28±5.6 |
Xerostomia | 21 (70) | 15 (50) |
Dyspnoea symptom burden# | 27 (90) | 15 (50) |
Data are presented as n, n (%) or mean±sd unless otherwise stated. AECOPD: acute exacerbation of COPD; GOLD: Global Initiative for Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BMI: body mass index. #: modified Medical Research Council score ≥2.